AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24708232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 23253084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB)
Number of subjects: 40
Study 23253084 — intervention group
Group type: COMPARATOR
Intervention: Control (without NMB)
Number of subjects: 40
Study 20124885 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 5 mg intravenously three times at 2‐min intervals
Number of subjects: 164
Study 20124885 — intervention group
Group type: COMPARATOR
Intervention: Morphine 5 mg intravenously followed by metoprolol 5 mg three times intravenously
Number of subjects: 164
Study 18216158 — intervention group
Group type: EXPERIMENTAL
Intervention: US and CD guided injection with sclerosing polidocanol
Number of subjects: 32
Study 18216158 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic lidocaine plus epinephrine
Number of subjects: 32
Study 16175618 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg per week for 1 year
Number of subjects: 34
Study 16175618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12960496 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 0
Study 12960496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate
Number of subjects: 0
Study 11058482 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (21 mg/day) with atypical antipsychotic medications
Number of subjects: 45
Study 11058482 — intervention group
Group type: COMPARATOR
Intervention: Nicotine transdermal patch (21 mg/day) with typical antipsychotic medications
Number of subjects: 45
Study 11058482 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch (21 mg/day) with either atypical or typical antipsychotic medications
Number of subjects: 45
Study 8610897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 14
Study 8610897 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 14
Study 1279502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine solution
Number of subjects: 0
Study 1279502 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline/lidocaine solution
Number of subjects: 0
Study 6233054 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic fields of extremely low frequency (EMF of ELF)
Number of subjects: 30
Study 6233054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EMF treatment)
Number of subjects: 30
Study 30700617 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid block combined with continuous transverse abdominis plane block (group TAP)
Number of subjects: 72
Study 30700617 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (group GA)
Number of subjects: 72
Study 30700617 — intervention group
Group type: COMPARATOR
Intervention: Subarachnoid block alone (group SAB)
Number of subjects: 72
Study 29126857 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (21.6mg)
Number of subjects: 25
Study 29126857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27435723 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement approach (EBQI) to tailoring Patient Aligned Care Teams (PACT) for women Veterans (WH-PACT)
Number of subjects: 12
Study 27435723 — intervention group
Group type: EXPERIMENTAL
Intervention: WH-PACT care
Number of subjects: 12
Study 27435723 — intervention group
Group type: EXPERIMENTAL
Intervention: EBQI-supported WH-PACT implementation
Number of subjects: 12
Study 24969339 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0-mm clear corneal micro-incision cataract surgery (MICS)
Number of subjects: 34
Study 24969339 — intervention group
Group type: COMPARATOR
Intervention: 2.65-mm small-incision cataract surgery (SICS)
Number of subjects: 34
Study 24969339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MICS and SICS groups
Number of subjects: 34
Study 22877814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based incentive
Number of subjects: 100
Study 22877814 — intervention group
Group type: COMPARATOR
Intervention: Control (no lottery intervention)
Number of subjects: 100
Study 22877814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based incentive (among patients with baseline INR below therapeutic range)
Number of subjects: 100
Study 22877814 — intervention group
Group type: COMPARATOR
Intervention: Control (among patients with baseline INR below therapeutic range)
Number of subjects: 100
Study 22877814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based incentive (among patients with low INR at baseline)
Number of subjects: 100
Study 20872304 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation‐based error training (SET)
Number of subjects: 32
Study 20872304 — intervention group
Group type: COMPARATOR
Intervention: Video‐based guided error training (VGET)
Number of subjects: 32
Study 18509324 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 5035
Study 18509324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5035
Study 16021649 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily at bedtime
Number of subjects: 585
Study 16021649 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (once- or twice-daily)
Number of subjects: 585
Study 16021649 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 585
Study 16021649 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 585
Study 16021649 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (for those on >1 basal insulin injection prior to study)
Number of subjects: 585
Study 16021649 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (for those on >1 basal insulin injection prior to study)
Number of subjects: 585
Study 12540987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 mg and 5 mg, n = 6)
Number of subjects: 12
Study 12540987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 12
Study 10751261 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs) including median, posterior tibial, and peroneal SEPs
Number of subjects: 69
Study 10751261 — intervention group
Group type: EXPERIMENTAL
Intervention: Derived spinal conduction time
Number of subjects: 69
Study 10751261 — intervention group
Group type: COMPARATOR
Intervention: Median CCTs
Number of subjects: 69
Study 8694155 — intervention group
Group type: EXPERIMENTAL
Intervention: mivacurium 0.2 mg.kg‐1
Number of subjects: 121
Study 8694155 — intervention group
Group type: COMPARATOR
Intervention: anaesthetic drugs alone
Number of subjects: 121
Study 1459169 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEPA (3 g n-3 fatty acids)
Number of subjects: 14
Study 3902241 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride solution
Number of subjects: 44
Study 3902241 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 44
Study 29663065 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal individual activation performed by relatives 6 days per week, cognitive stimulation once a week by an external person, over a 6-month intervention period.
Number of subjects: 72
Study 29663065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 30577611 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI)
Number of subjects: 56
Study 30577611 — intervention group
Group type: COMPARATOR
Intervention: Soy protein isolate (SPI)
Number of subjects: 56
Study 27669178 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored physical activity intervention
Number of subjects: 266
Study 27669178 — intervention group
Group type: COMPARATOR
Intervention: Wellness control group
Number of subjects: 266
Study 24994841 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM excision
Number of subjects: 134
Study 24994841 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 134
Study 23270253 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitory Stimulation Interval Exercise (TSIE)
Number of subjects: 30
Study 23270253 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Moderate Exercise (CME)
Number of subjects: 30
Study 20424555 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (12 g daily)
Number of subjects: 54
Study 20424555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 19078834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital abciximab treatment
Number of subjects: 101
Study 19078834 — intervention group
Group type: COMPARATOR
Intervention: Periprocedural abciximab treatment
Number of subjects: 101
Study 15950849 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 15 mL of 0.5% bupivacaine
Number of subjects: 24
Study 15950849 — intervention group
Group type: COMPARATOR
Intervention: Multiple injections (3 injections) of 15 mL of 0.5% bupivacaine (5 mL each at C2, C3, C4)
Number of subjects: 24
Study 12027926 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Participation Programme (PP)
Number of subjects: 165
Study 12027926 — intervention group
Group type: COMPARATOR
Intervention: Standard Consultation (SC)
Number of subjects: 165
Study 10710970 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive ($1)
Number of subjects: 600
Study 10710970 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentive (Control)
Number of subjects: 600
Study 7669649 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg SDZ IMM 125 daily
Number of subjects: 59
Study 7669649 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg SDZ IMM 125 daily
Number of subjects: 59
Study 7669649 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg SDZ IMM 125 daily
Number of subjects: 59
Study 7669649 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg SDZ IMM 125 daily
Number of subjects: 59
Study 7669649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 2257964 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine taken once nightly
Number of subjects: 50
Study 2257964 — intervention group
Group type: COMPARATOR
Intervention: 400 mg cimetidine taken twice daily
Number of subjects: 50
Study 7003687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunerin (oral decongestant: brompheniramine maleate and phenylpropanolamine hydrochloride)
Number of subjects: 26
Study 7003687 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 26
Study 31937137 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization + best medical therapy + structured exercise therapy
Number of subjects: 158
Study 31937137 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy + structured exercise therapy (nonrevascularization group)
Number of subjects: 158
Study 31937137 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization strategy
Number of subjects: 158
Study 31937137 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive treatment approach
Number of subjects: 158
Study 30829901 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - 3‐min intervals at 40% and 80% of V˙O2max, n = 18, for 30 min·d, 5 d·wk for 6 wk
Number of subjects: 54
Study 30829901 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT) - sustained 60% of V˙O2max, n = 18, for 30 min·d, 5 d·wk for 6 wk
Number of subjects: 54
Study 30829901 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18) - no exercise intervention
Number of subjects: 54
Study 28746558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer intervention
Number of subjects: 95
Study 28746558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prayer)
Number of subjects: 95
Study 26673225 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation‐Response‐based Mental Health Promotion (RR‐MHP) program (Open and Calm)
Number of subjects: 72
Study 26673225 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 72
Study 23566529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT)
Number of subjects: 63
Study 23566529 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT)
Number of subjects: 63
Study 22013800 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaozhang Recipe (XR)
Number of subjects: 84
Study 22013800 — intervention group
Group type: COMPARATOR
Intervention: Fuzheng Huayu Capsule
Number of subjects: 84
Study 19222595 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 100 mg/day
Number of subjects: 323
Study 19222595 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 300 mg/day
Number of subjects: 323
Study 19222595 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 600 mg/day
Number of subjects: 323
Study 19222595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 16505397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadolinium chelate (group A)
Number of subjects: 60
Study 16505397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mmol/kg gadolinium chelate (group B)
Number of subjects: 60
Study 16505397 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 60
Study 14697926 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 43
Study 14697926 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (N-BG)
Number of subjects: 43
Study 11104316 — intervention group
Group type: EXPERIMENTAL
Intervention: Beh (intensive, multi-faceted behavior therapy program)
Number of subjects: 579
Study 11104316 — intervention group
Group type: EXPERIMENTAL
Intervention: MedMgt (carefully titrated and monitored medication management strategy)
Number of subjects: 579
Study 11104316 — intervention group
Group type: EXPERIMENTAL
Intervention: Comb (well-integrated combination of behavior therapy and medication management)
Number of subjects: 579
Study 11104316 — intervention group
Group type: COMPARATOR
Intervention: CC (community comparison group)
Number of subjects: 579
Study 9158270 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8082361 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 20 mg by mouth, three times a day for 7 days
Number of subjects: 14
Study 8082361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8082361 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (1 ml/kg body weight, 50 percent)
Number of subjects: 14
Study 2671121 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (doses reducing resting heart rate by 25%)
Number of subjects: 174
Study 2671121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin K)
Number of subjects: 174
Study 2671121 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (in subset without ascites)
Number of subjects: 174
Study 2671121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subset without ascites)
Number of subjects: 174
Study 2671121 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (in ascites-free period)
Number of subjects: 174
Study 2671121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in ascites-free period)
Number of subjects: 174
Study 2671121 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (in patients with ascites)
Number of subjects: 174
Study 2671121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with ascites)
Number of subjects: 174
Study 919994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical preparation with antibiotics (lincomycline, neomycine, polymyxine, kanamycine, bacitracine, nystatine)
Number of subjects: 46
Study 919994 — intervention group
Group type: COMPARATOR
Intervention: Mechanical preparation alone
Number of subjects: 46
Study 919994 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative use of antibiotics for local or general infection
Number of subjects: 46
Study 30649154 — intervention group
Group type: EXPERIMENTAL
Intervention: Running cuticular closure with 2-mm spacing
Number of subjects: 50
Study 30649154 — intervention group
Group type: COMPARATOR
Intervention: Running cuticular closure with 5-mm spacing
Number of subjects: 50
Study 27834120 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG + LLLT (test group)
Number of subjects: 40
Study 27834120 — intervention group
Group type: COMPARATOR
Intervention: CTG (control group)
Number of subjects: 40
Study 25666221 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed DESI in DVD format
Number of subjects: 2550
Study 25666221 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared medical appointment (SMA) to view the DESI
Number of subjects: 2550
Study 25666221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mailed DESI and SMA
Number of subjects: 2550
Study 25666221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2550
Study 24975892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bixalomer 1.5 g/day
Number of subjects: 124
Study 24975892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bixalomer 3.0 g/day
Number of subjects: 124
Study 24975892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bixalomer 4.5 g/day
Number of subjects: 124
Study 24975892 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer hydrochloride (HCl)
Number of subjects: 124
Study 24975892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 22559260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stent implantation after pre-dilation with a drug-eluting balloon (n=10)
Number of subjects: 30
Study 22559260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stent implantation followed by post-dilation with a drug-eluting balloon (n=10)
Number of subjects: 30
Study 22559260 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent implantation alone (n=10)
Number of subjects: 30
Study 19528367 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin
Number of subjects: 71
Study 19528367 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg dapagliflozin
Number of subjects: 71
Study 19528367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 17333949 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help for depression
Number of subjects: 24
Study 15287853 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine‐interferon (IFN)‐alpha combination therapy
Number of subjects: 16
Study 11246937 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Pad A (low, uniform static magnetic field of negative polarity)
Number of subjects: 0
Study 11246937 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Pad B (low static magnetic field that varied spatially and in polarity)
Number of subjects: 0
Study 11246937 — intervention group
Group type: COMPARATOR
Intervention: Sham groups (inactive magnets, identical in appearance and texture to functional pads)
Number of subjects: 0
Study 11246937 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group (continued established treatment regimens)
Number of subjects: 0
Study 9169288 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 10
Study 1583328 — intervention group
Group type: COMPARATOR
Intervention: IL-1 production in response to leishmania antigens, heat-killed Listeria organisms, and lipopolysaccharide
Number of subjects: 16
Study 1583328 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 production post-therapy
Number of subjects: 16
Study 1583328 — intervention group
Group type: COMPARATOR
Intervention: TNF production in response to leishmania antigens
Number of subjects: 16
Study 1583328 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TNF levels
Number of subjects: 16
Study 3515060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing medical records (experimental group)
Number of subjects: 203
Study 3515060 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sharing of medical records)
Number of subjects: 203
Study 3515060 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-educated patients (experimental group)
Number of subjects: 203
Study 31946867 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham stimulation during Instances Task)
Number of subjects: 0
Study 31946867 — intervention group
Group type: EXPERIMENTAL
Intervention: No stimulation group
Number of subjects: 0
Study 30274112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine-linked antibacterial surface coating on nasal prongs
Number of subjects: 48
Study 30274112 — intervention group
Group type: COMPARATOR
Intervention: Non-coated nasal prongs
Number of subjects: 48
Study 27203302 — intervention group
Group type: EXPERIMENTAL
Intervention: G1‐PLUS™/G2‐PLUS™ sequential medium (Vitrolife)
Number of subjects: 60
Study 27203302 — intervention group
Group type: COMPARATOR
Intervention: GV BLAST™ sole medium (Ingamed)
Number of subjects: 60
Study 24480867 — intervention group
Group type: COMPARATOR
Intervention: Normotensive Hispanic women at baseline
Number of subjects: 4680
Study 24480867 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehypertensive participants at baseline
Number of subjects: 4680
Study 24480867 — intervention group
Group type: COMPARATOR
Intervention: Hypertensive participants compared to normotensive
Number of subjects: 4680
Study 22886839 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm humidified CO₂ (37°C, 100% relative humidity, 10 L/min)
Number of subjects: 83
Study 22886839 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard warming measures)
Number of subjects: 83
Study 19922752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry condition
Number of subjects: 66
Study 19922752 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese group
Number of subjects: 66
Study 19922752 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-weight group
Number of subjects: 66
Study 19922752 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual probe task
Number of subjects: 66
Study 19922752 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye-tracking data
Number of subjects: 66